...the last of which expires in March 2033. It has already settled patent litigation with Wockhardt Ltd....

...the last of which expires in March 2033. It has already settled patent litigation with Wockhardt Ltd....

...said it believes FDA's concerns are related to GMP systems at "several" facilities operated by Wockhardt Ltd....

...from $137 after Jazz settled two patent infringement suits regarding Xyrem sodium oxybate. Jazz granted Wockhardt Ltd....

...pneumonia (HAP). Early next year, Wockhardt plans to start Phase III testing of both compounds. Wockhardt...
...WCK 771 is an IV tricyclic fluoroquinolone, and WCK 2349 is an oral broad-spectrum antibiotic. Wockhardt Ltd....

...pneumonia (HAP). Early next year, Wockhardt plans to start Phase III testing of both compounds. Wockhardt...
...WCK 771 is an IV tricyclic fluoroquinolone, and WCK 2349 is an oral broad-spectrum antibiotic. Wockhardt Ltd....

...Avanir and Wockhardt settled a 2011 suit alleging Wockhardt's ANDA for a generic version of Nuedexta...
...treat pseudobulbar affect (PBA) infringes Avanir's U.S. Patent Nos. 7,659,282 and RE38,115. Under the settlement, Wockhardt...
...BioCentury, Aug. 22, 2011 & Sept. 9, 2013). Avanir Pharmaceuticals Inc. (NASDAQ:AVNR), Aliso Viejo, Calif. Wockhardt Ltd....

...7, 2012). In 2010, Orion granted Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA, Mumbai, India) and Wockhardt Ltd....
...April 1, 2012, while its rights to market other strengths begin on Oct. 2, 2012. Wockhardt's...

...NASDAQ:MYL), Canonsburg, Pa. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Pfizer Inc. (NYSE:PFE), New York, N.Y. Wockhardt Ltd....

...April 2). In 2010, Orion granted Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA, Mumbai, India) and Wockhardt Ltd....
...April 1, 2012, while its rights to market other strengths begin on Oct. 2, 2012. Wockhardt's...